Tag: Quantitative Systems Pharmacology
Dose Optimization using the Gene Therapy Virtual Twin Platform
This blog explains how using the Gene Therapy Virtual Twin™ Platform can help optimize dosing for patients.
Virtual Patients Refine Search for Safe & Effective Immuno-oncology Combo Therapies
By Vijayalakshmi Chelliah, Georgia Lazarou, Piet van der Graaf and Andrzej Kierzek Immuno-oncology (IO) represents an elegant solution; it uses a patient’s own immune system to fight their cancer. Early IO research used monoclonal antibodies to induce an immune response from patients’ PD1/PD-L1 and CTLA4 receptors, which serve as immune system checkpoints, successfully achieving long-term … Continued
Virtual Twin Patients Can Bridge Data Gaps for COVID-19 Halted Clinical Trials
The virtual twin approach combines limited clinical data with biological principles to make patient level predictions which could help recover halted trials.
Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm
Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) the aim is to direct the patient’s own immune system to fight cancer. After remarkable successes of antibodies targeting PD1/PD‐L1 and CTLA4 receptors in targeted patient populations, the focus of further development … Continued
Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology
Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat cancer. In addition to clinically validated immune cell re‐targeting, bsAbs are being designed for tumor targeting and as dual immune modulators. Explorative preclinical and emerging clinical data indicate potential for enhanced efficacy and reduced systemic toxicity. However, bsAbs are a … Continued
Accelerating Vaccine Development: Applications to COVID-19 and Future Pandemics
A QSP Modeling Approach for Neurodegenerative Disease Drug Development
A QSP model was built to evaluate its use in drug discovery for complex neurodegenerative diseases, e.g. Alzheimer’s.
Simcyp: 20 Years of Innovation
The consortium members have partnered with Simcyp and Certara during the past 20 years to advance the science of drug development through modeling & simulation